Definitions

OklahomaRegulations

Ask Donna

How this section applies to your facts.

Oklahoma Administrative Code › Title 450 › OAC 450:70-1-2

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

The following words or terms, when used in this chapter, shall have the

following meaning, unless the context clearly indicates otherwise:

"Accreditation" means the process of review and acceptance by a nationally

recognized accreditation body.

"Accreditation body" means a body that has been approved by SAMHSA to

accredit opioid treatment programs using opioid agonist or partial agonist

treatment medications.

"Administer" means the direct application of a prescription drug by ingestion

or any other means to the body of a person served by a licensed practitioner, or

the patient at the direction of, or in the presence of, a practitioner.

"Administrative withdrawal" means medically supervised withdrawal

involving the gradual tapering of dose of medication over time, coinciding with the

usually involuntary discharge from medication assisted treatment. Administrative

withdrawal typically results from non-payment of fees, violent or disruptive

behavior, incarceration or other confinement.

"Approved narcotic drug" means a drug approved by the United States

Food and Drug Administration for maintenance and/or detoxification of a person

physiologically dependent upon opioid drugs.

"ASAM criteria" means the most current edition of the American Society of

Addiction Medicine's published criteria for admission to treatment, continued

services, and discharge.

"Biopsychsocial assessment" means in-person interviews conducted by a

LBHP or Licensure Candidate designed to elicit historical and current information

regarding the behavior and experiences of a person served, and are designed to

provide sufficient information for problem formulation, intervention planning, case

management needs, and formulation of appropriate substance abuse-related

treatment and service planning.

"Buprenorphine" means a partial agonist, Schedule III narcotic approved for

use in opioid dependence treatment.

"CARF" means the Commission on the Accreditation of Rehabilitation

Facilities.

"Central registry" means a document or database to which an OTP shall

report identifying information about individuals who are applying for or

Unofficial Copy: OAC Title 450:70

7

Effective 09/15/2025

undergoing medically supervised withdrawal or maintenance treatment on an

approved opioid agonist or partial agonist to a central record system approved by

the Commissioner or designee.

"Certification" means the process by which ODMHSAS or SAMHSA

determine that an OTP is qualified to provide opioid treatment under applicable

State and Federal standards.

"Chain of custody" means the process of protecting items so that

movement, possession and location are secure and documented and there is no

possibility for altering or otherwise tampering with the item.

"Chronic pain disorder" means an ongoing condition or disorder consisting

of chronic anxiety, depression, anger and changed lifestyle, all with a variable but

significant level of genuine neurologically based pain. The pain becomes the

main focus of the person served, and results in significant distress and

dysfunction.

"Clinical Opioid Withdrawal Scale" or "COWS" means a well validated,

standardized assessment instrument for evaluating the severity of withdrawal

through the identification of objective and subjective symptoms and the severity

of these symptoms.

"Clinical record" or "treatment record" means the collection of written

information about the evaluation or treatment of a person served that includes

the intake data, evaluation, service plan, description of services provided,

medications as prescribed, continuing care plan, and discharge information.

"Clinical supervision" means an organized process by which

knowledgeable and skilled supervisors systematically and routinely provide

ongoing and in-depth review of direct service providers' performance.

"COA" means the Commission on Accreditation.

"Comprehensive

maintenance

treatment"

means

dispensing

or

administering an approved opioid agonist or partial agonist medication at stable

dosage levels for a period in excess of 21 days for opioid use disorder; and

providing medical, clinical and educational services to the person served with

opioid use disorder.

"Continuing care plan" or "discharge summary" means a written plan of

recommendations and specific referrals for implementation of continuing care

services, including medications, developed with the knowledge and cooperation

of the person served.

"Co-occurring disorder" or "COD" means any combination of mental health

and substance use disorder symptoms or diagnoses as determined by the

current Diagnostic and Statistical Manual of Mental Disorders that affect a person

served.

"Critical incident" means an occurrence or set of events inconsistent with

the routine operation of a facility, service setting, or otherwise routine care of a

person served. Critical incidents specifically include but are not necessarily

limited to the following: adverse drug events; self-destructive behavior; deaths

and injuries to persons served, staff and visitors; medication errors; persons

receiving residential treatment that are absent without leave (AWOL); neglect or

abuse of a person served; fire; unauthorized disclosure of information; damage to

Unofficial Copy: OAC Title 450:70

8

Effective 09/15/2025

or theft of property belonging to persons served or the facility; other unexpected

occurrences; or events potentially subject to litigation. A critical incident may

involve multiple individuals or results.

"Cultural competency" means the ability to recognize, respect, and address

the unique needs, worth, thoughts, communications, actions, customs, beliefs

and values that reflect an individual's racial, ethnic, religious, sexual orientation,

and/or social group.

"DEA" means Drug Enforcement Administration.

"Discharge planning" means the process, beginning at admission of

determining a consumer's continued need for treatment services and developing

a plan to address ongoing consumer recovery needs.

"Diskette" means a compressed wafer form of methadone intended to be

dissolved in water for consumption.

"Dispense" means preparing, packaging, compounding and labeling for

delivery, a prescription drug in the course of professional practice to an ultimate

user by the lawful order of a physician.

"Diversion" means the unauthorized or illegal transfer of an opioid agonist or

partial agonist treatment medication.

"Diversion control plan" or "DCP" means documented procedures to

reduce the possibility that controlled substances are used for any purpose other

than legitimate use.

"Drug test" means the assessment of an individual to determine the

presence or absence of illicit or non-prescribed drugs or alcohol or to confirm

maintenance levels of treatment medication(s), by a methodology approved by

the OTP medical director based on informed medical judgment and conforming

to State and Federal law. This may include blood testing, oral-fluid and urine

testing.

"Exception request process" means a process recording the justification of

the need to make a change in treatment protocol for person receiving medication

assisted treatment for opioid use disorder and submitted to SAMHSA using form

SMA-168.

"FDA" means the Federal Food and Drug Administration.

"Federal opioid treatment standards" means the established standards of

SAMHSA, CSAT and the DEA that are used to determine whether an OTP is

qualified to engage in medication assisted opioid treatment.

"HIPAA" means Health Insurance Portability and Accountability Act

"Holiday" means those days recognized by the State of Oklahoma as

holidays.

"Individual Placement and Support" or "IPS" means an evidence based

specific type of employment and education service to help people with mental

illness, substance use disorders or co-occurring disorders, find and keep

competitive employment.

"Individualized service planning" means the ongoing process by which a

clinician and the person served identify and rank problems, establish agreed

upon goals, and decide on the treatment process and resources to be utilized.

"Interim maintenance treatment" means maintenance treatment provided in

Unofficial Copy: OAC Title 450:70

9

Effective 09/15/2025

conjunction with appropriate medical services while a person served is awaiting

transfer to a program that provides comprehensive maintenance treatment.

"JC" or "TJC" means the Joint Commission.

"Licensed Behavioral Health Professional" or "LBHP" means:

(A) An Allopathic or Osteopathic Physician with a current license and

board certification in psychiatry or board eligible in the state in which

services are provided, or a current resident in psychiatry;

(B) An Advanced Practice Registered Nurse licensed as a registered

nurse with a current certification of recognition from the board of nursing in

the state in which services are provided and certified in a psychiatric

mental health specialty;

(C) A Clinical Psychologist who is duly licensed to practice by the State

Board of Examiners of Psychologists;

(D) A Physician Assistant who is licensed in good standing in Oklahoma

and has received specific training for and is experienced in performing

mental health therapeutic, diagnostic, or counseling functions;

(E) A practitioner with a license to practice in the state in which services

are provided by one of the following licensing boards:

(i) Social Work (clinical specialty only);

(ii) Professional Counselor;

(iii) Marriage and Family Therapist;

(iv) Behavioral Practitioner; or

(v) Alcohol and Drug Counselor.

"Licensure candidate" means practitioners actively and regularly receiving

board approved supervision, and extended supervision by a fully licensed

clinician if board's supervision requirement is met but the individual is not yet

licensed, to become licensed by one of the following licensing boards:

(A) Psychology;

(B) Social Work (clinical specialty only);

(C) Professional Counselor;

(D) Marriage and Family Therapist;

(E) Behavioral Practitioner; or

(F) Alcohol and Drug Counselor.

"Liquid methadone" means a liquid concentrate of methadone meant to be

mixed with water for ingestion.

"Lock box" means a container with a combination lock or key lock entry

system for securing take home medications. The box must have the ability to

lock and should be secure enough to thwart access by children.

"Long-term care facility" means a facility that provides rehabilitative,

restorative, and/or ongoing services to those in need of assistance with activities

of daily living. Long-term care facilities include extended acute care facilities;

rehabilitation centers; skilled nursing facilities; permanent supportive housing;

assisted living facilities; and chronic care hospitals.

"Long-term withdrawal management" means detoxification treatment for a

period of more than 30 days but less than 180 days.

"Medical director" means a physician, licensed to practice medicine in

Unofficial Copy: OAC Title 450:70

10

Effective 09/15/2025

Oklahoma, who assumes responsibility for the administration of all medical

services performed by an OTP, either by performing them directly or by

delegating specific responsibility to authorized program physicians and

healthcare professionals functioning under the medical director's direct

supervision, unless otherwise indicated in this chapter. This includes ensuring

the program is in compliance with all federal, state, and local laws and

regulations regarding the medical treatment of dependence on an opioid drug.

"Medical withdrawal" means a condition created by administering an opioid

agonist or partial agonist treatment medication in decreasing doses to an

individual to alleviate adverse physical or psychological effects of withdrawal

from the continuous or sustained use of an opioid drug and as a method of

bringing the individual to a drug-free state.

"Medication for Opioid Use Disorder" or "MOUD" means medications,

including opioid agonist medications, approved by the Food and Drug

Administration under section 505 of the Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 355), for use in the treatment of opioid use disorder.

"Medication unit" means a satellite facility established as part of, but

geographically separate from, an OTP from which appropriately licensed

practitioners dispense or administer an opioid agonist or partial agonist treatment

medication or collect samples for drug testing or analysis. Medication units

include mobile and brick and mortar facilities.

"Non-oral methadone" means an injectable form of methadone not allowed

for use by an OTP.

"Nurse practitioner" means a registered nurse who is prepared through

advanced education and clinical training, to provide a wide range of health care

services.

"ODMHSAS" means the Oklahoma Department of Mental Health and

Substance Abuse Services.

"Oklahoma Administrative Code" or "OAC" means the publication

authorized by 75 O.S. § 256 known as The Oklahoma Administrative Code, or,

prior to its publication, the compilation of codified rules authorized by 75 O.S. §

256(A) (1) (a) and maintained in the Office of Administrative Rules.

"OBNDD" means the Oklahoma Bureau of Narcotics and Dangerous Drug

Control.

"Opiate drug" means any of a class of drugs also called narcotics derived

from the opium poppy or containing opium and with analgesic or sedative effects

that can form sustain or enhance addiction and physical dependency.

"Opioid agonist" means a drug that has an affinity for and stimulates

physiologic activity at cell receptors in the central nervous system normally

stimulated by opioids. Methadone is an opioid agonist.

"Opioid agonist or partial agonist treatment medication" means a

prescription medication, such as methadone, buprenorphine or other substance

scheduled as a narcotic under the Federal Controlled Substances Act (21 U.S.C.

Section 811) that is approved by the U.S. Food and Drug Administration for use

in the treatment of opiate addiction or dependence.

"Opioid antagonist" means a drug that binds to cell receptors in the central

Unofficial Copy: OAC Title 450:70

11

Effective 09/15/2025

nervous system that normally are bound by opioid psychoactive substances and

that blocks the activity of opioids at these receptors without producing the

physiologic activity produced by opioid agonists. Naltrexone is an opioid

antagonist.

"Opioid dependence" means a cluster of cognitive, behavioral, and

physiological symptoms in which an individual continues use of opioids despite

significant opioid-induced problems. Opioid dependence is characterized by

repeated self-administration resulting in opioid tolerance, withdrawal symptoms,

and compulsive drug-taking. Dependence may occur with or without the

physiological symptoms of tolerance and withdrawal.

"Opioid drug" means any of a class of drugs also called narcotics, having a

dependence-forming or dependence-sustaining liability similar to morphine.

Originally a term for synthetic narcotics only, but for the purposes of this chapter

and unless otherwise specified, currently used to describe both opium based and

synthetic narcotics. These drugs have analgesic or sedative effects.

"Opioid partial agonist" means a drug that binds to, but incompletely

activates, opiate receptors in the central nervous system, producing effects

similar to those of an opioid agonist but, at increasing doses, does not produce

as great an agonist effect as do increased doses of an agonist. Buprenorphine is

a partial opioid agonist.

"Opioid Treatment Program (OTP)" means an organization which has been

certified by ODMHSAS to provide therapeutic services and FDA-approved

medications for opioid use disorder, referred to in statute as an Opioid

Substitution Treatment Program.

"Opioid Use Disorder treatment" means the dispensing of MOUD, along

with the provision of a range of medical and behavioral health services, as

clinically necessary and based on an individualized assessment and a mutually

agreed-upon care plan, to an individual to alleviate the combination of adverse

medical, psychological, or physical effects associated with an Opioid Use

Disorder.

"Pain management" means the successful management of chronic pain or a

chronic pain disorder.

"Parenteral" means injected, infused or implanted, used to describe drug

administration other than oral or anal.

"Person served" means an individual, adult, adolescent, or child, who has

applied for, is receiving or has received evaluation or treatment services from a

facility operated or certified by ODMHSAS or with which ODMHSAS contracts

and includes all persons referred to in OAC Title 450 as client(s), consumer(s),

patient(s) or resident(s) or a combination thereof.

"Physician assistant" means a licensed or certified mid-level medical

practitioner who works under the supervision of a licensed physician (MD) or

osteopathic physician (DO).

"Program physician" means a licensed physician who provides medical

treatment and counsel to the persons served by an OTP while under the

supervision of the medical director.

"Program sponsor" means a person named in the application for an OTP

Unofficial Copy: OAC Title 450:70

12

Effective 09/15/2025

permit who is responsible for the operation of the OTP and who assumes

responsibility for all its employees, including any practitioners, staff, or other

persons providing medical, rehabilitative, or therapy services at the program or

any of its medication units. The program sponsor need not be a licensed

physician but shall employ a licensed physician for the position of medical

director.

"Psychotherapy" or "Therapy" means a goal directed process using

generally accepted clinical approaches provided face-to-face by a Licensed

Behavioral Health Professional (LBHP) or Licensure Candidate with consumers

in individual, group, or family settings to promote positive, emotional, or

behavioral change.

"Rehabilitation Services" means face-to-face individual or group services

provided by qualified staff to develop skill necessary to perform activities of daily

living and successful integration into community life. Rehabilitation services must

be provided by a Licensed Behavioral Health Professional (LBHP), Licensure

Candidate, Certified Alcohol and Drug Counselor (CADC) or Certified Behavioral

Health Case Manager II (CM II).

"SAMHSA" means the Substance Abuse and Mental Health Services

Administration.

"Sentinel event" means a type of critical incident that is an unexpected

occurrence involving the death or serious physical or psychological injury to a

person served, staff member, or visitor, or risk thereof. Serious injury specifically

includes loss of limb or function. The phrase "or risk thereof" includes a variation

in approved processes which could carry a significant chance of a serious

adverse outcome. These events signal the need for immediate investigation and

response. Sentinel events include, but are not limited to, suicide, homicide,

assault and other forms of violence, including domestic violence or sexual

assault, and adverse drug events resulting in serious injury or death. Sentinel

events include occurrences that take place at the facility and/or during the

delivery of services, as well as suicide and unintentional drug overdose deaths

that occur at any time while a person receiving outpatient services is an active

client, within seventy-two (72) hours of contact after mobile/outpatient crisis

intervention services are provided, and within seventy-two (72) hours of

discharge from inpatient and residential settings, including sites certified under

Chapter 23 of this Title.

"Service Provider" means a person who is allowed to provide services for

those with substance use disorders within the regulation and scope of their

certification level or license.

"Short-term withdrawal management" means detoxification treatment for a

period not in excess of 30 days.

"Split dosing" means dispensing of a single dose of MOUD as separate

portions to be taken within a 24-hour period. Split dosing is indicated among, but

not limited to, those patients who: possess a genetic variant which increases

methadone metabolism; concurrently take other medications or drink alcohol that

also induce hepatic enzymes leading to more rapid metabolism of methadone;

who are pregnant; or for whom methadone or buprenorphine are being used to

Unofficial Copy: OAC Title 450:70

13

Effective 09/15/2025

treat a concurrent pain indication in addition to the diagnosis of OUD. This leads

to more stable, steady-state medication levels.

"State Opioid Treatment Authority" or "SOTA" means the agency

designated by the Governor or other appropriate official designated by the

Governor to exercise the responsibility and authority within the State or Territory

for governing the treatment of opioid dependence with an opioid drug. For

Oklahoma it is the Oklahoma Department of Mental Health and Substance Abuse

Services.

"STD" means sexually transmitted disease.

"Tablet methadone" means methadone in a tablet form intended to be taken

orally. For the purposes of this chapter diskettes will not be considered to be

tablet methadone. Tablet methadone is not allowed for use by an OTP.

" Take-home dose" or "take-home medication" means one or more doses

of an opioid agonist or partial agonist treatment medication dispensed to a

person served for use off the premises.

"Therapeutic hour(s)" means the amount of time in which the person served

was engaged with a service provider in identifying, addressing, and/or resolving

those issues that have been identified in that individual’s treatment plan.

"Urine drug screen" means a urine sample taken to determine if metabolites

are present indicating the use of drugs.

"Withdrawal management" means the dispensing of a MOUD in decreasing

doses to an individual to alleviate adverse physical effects incident to withdrawal

from the continuous or sustained use of an opioid and as a method of bringing

the individual to an opioid-free state within such period. Long-term withdrawal

management refers to the process of medication tapering that exceeds thirty (30)

days.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.